CARD9 as a potential therapeutic target in lung cancer
Ruanmei Sheng1,2, Zhiwen Yang3
1Department of Emergency Medicine and Intensive Care, Shanghai Songjiang District Central Hospital, 201600 Shanghai, China.
Insights
Caspase recruitment domain-containing protein 9 (CARD9) regulates innate immunity and is increasingly linked to lung cancer development. This review explores CARD9's clinical significance and molecular roles in lung cancer progression.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Caspase recruitment domain-containing protein 9 (CARD9) is a key regulator of innate immunity, primarily expressed in myeloid cells.
- Emerging evidence highlights the significant role of CARD9 in the pathogenesis and progression of lung cancer.
Purpose of the Study:
- To review the clinical significance of CARD9 in lung cancer.
- To elucidate the potential molecular mechanisms underlying CARD9's role in lung cancer development.
Main Methods:
- Literature review of studies investigating CARD9 in innate immunity and lung cancer.
- Analysis of clinical data and molecular pathways associated with CARD9 in lung cancer.
Main Results:
- CARD9's expression and function are implicated in various stages of lung cancer.
- Specific molecular pathways involving CARD9 in lung cancer pathogenesis are identified.
Conclusions:
- CARD9 represents a potential therapeutic target for lung cancer.
- Further research into CARD9's mechanisms could lead to novel treatment strategies for lung cancer.
Abstract:
Caspase recruitment domain-containing protein 9 (CARD9) is highly expressed in myeloid cells and has been identified as a central regulator of innate immunity. Increasingly, studies demonstrate that CARD9 also plays a critical role in the development of lung cancer. This review focuses on the clinical significance and potential molecular mechanisms that CARD9 plays in lung cancer.
